Metabolic, transcriptomic, and proteomic adaptations in pancreatic ductal adenocarcinoma-patient derived xenograft models across serial passages
Pengfei GuoHaizong FangHan ShiJunrong ZhangGe SongClaire FanXinyu QiuXianchao LinWen ShiJianghua FengHeguang HuangTianhong Teng
Abstract
PDX models undergo adaptive changes during serial passaging while retain primary tumor characteristics, making them a valuable tool for understanding tumor evolution and informing therapeutic strategies, provided that passage-related drift is carefully considered.
Metrics
Citation History
Topics
Related Documents
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
Aubrey L. MillerPatrick L. GarciaTracy L. GamblinRebecca B. VanceKarina J. Yoon
Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor
Wen ShiXianchao LinWei LuoYu PanFei LiaoZhenzhao WangBohan ZhanJianghua FengHeguang Huang
Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient‐derived xenograft models
Alessia AnastasiaLaura FormentiPaola OstanoLucia MinoliAndrea ResoviLavinia MorosiClaudia FioravantiEdoardo MicottiCristina MatteoEugenio ScanzianiGiovanna ChiorinoRaffaella GiavazziCarmen GhilardiDorina Belotti
The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
Patrick L. GarciaAubrey L. MillerKelly M. KreitzburgLeona N. CouncilTracy L. GamblinJohn D. ChristeinMarty J. HeslinJ. Pablo ArnolettiJoseph H. RichardsonD ChenC. Alexandra HannaS L CramerEddy S. YangJun QiJames E. Bradner
Abstract C060: Characterization of a collection of patient-derived xenograft models for pancreatic ductal adenocarcinoma translational research
M. YáñezEnrique J. ArenasTeresa MacarullaTian TianJoaquı́n ArribasSofía LlorenteCarles Fabregat-FrancoMarta EscorihuelaFlorian CastetJessica QuerolMaría Teresa Salcedo